ReviewCurrent rheumatology reports2026
NOD2-Related Multisystem Inflammatory Disorders and Recent Advances.
Review in Current rheumatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics characterization of Yao syndrome identifies three pathophysiological axes and disease-specific divergence from Blau syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Yao syndrome: Report of 3 cases with a family history.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewNucleotide-binding oligomerization domain-containing protein 2 (NOD2) is an intracellular innate immune sensor. Its functions have been extensively studied. Variants in the NOD2 gene are associated with several human diseases. This report provides a comprehensive review of these diseases and biomedical and immunological roles of NOD2. RECENT
findingsBlau syndrome is an autosomal dominant disease primarily occurring in children and is caused by highly penetrant NOD2 variants. Approximately 40% of Caucasian patients with Crohn's disease (CD) are associated with three main NOD2 variants of low penetrance. Yao syndrome (YAOS), a recently reported novel disease, possesses characteristic clinical pattern or constellation of recurrent fever, dermatitis, arthralgia, distal leg swelling, gastrointestinal, sicca-like symptoms, and eyelid swelling among others. This disease is associated with specific NOD2 variants including the CD-associated three main variants. Our recent large case-control study of population genetics and haplotype analyses confirms the association between certain NOD2 variants and YAOS and the coinheritance in cis of the commonly encountered variants. Molecular testing is required for the diagnosis of YAOS. The prevalence of the disease is estimated to approach that of CD. There are identified effective drugs to manage this condition. Functional studies of NOD2 have revealed its contribution to both innate and adaptive immune responses, and there are interplays between these cellular components and cytokines. NOD2 has been extensively studied for innate immune response. Specific NOD2 variants are associated with different diseases, highlighting the fact that the same genotype can contribute to different phenotypes. Further studies are warranted to focus on adaptive immunity and bridge the gap between innate and adaptive immune responses in individual diseases.
Indexed as
Identifiers
41678017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.